You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Article info

Article menu

Download PDFPDF

XML
Research Article
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Authors

  • Chu-Yu Jing Fudan University Shanghai Cancer Center 270 Dong-An Road 200032 Shanghai People’s Republic of China The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Yi-Peng Fu Department of breast surgeryThe Obstetrics & Gynecology Hospital of Fudan University 419 Fangxie Road 200090 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Yong Yi The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Mei-Xia Zhang The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Su-Su Zheng The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Jin-Long Huang The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Wei Gan The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Xin Xu The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Jia-Jia Lin The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Juan Zhang The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Shuang-Jian Qiu The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles
  • Bo-Heng Zhang The Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education 180 Fenglin Road 200032 Shanghai People’s Republic of China Center for evidence-based medicine, Shanghai Medical SchoolFudan University 200032 Shanghai People’s Republic of China PubMed articlesGoogle scholar articles

Citation

Jing C, Fu Y, Yi Y, et al
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
Journal for ImmunoTherapy of Cancer 2019;7:77. doi: 10.1186/s40425-019-0554-8
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.